Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL

John DiPersio, Naval Daver, Noelle Frey and Richard Stone

Immunotherapy is an exciting area, with advocates, sceptics and those who remain undecided without further research. The 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, hosted a captivating session on the topic of immunotherapy for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In this panel discussion, recorded during the meeting, the chair of the session, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, is joined by session speakers Naval Daver, MD, from MD Anderson Cancer Center, Houston, TX, John DiPersio, MD, PhD, of Washington University School of Medicine, Washington, WA, and Noelle Frey, MD, of the University of Pennsylvania, Philadelphia, PA. Dr Daver covers his talk on checkpoint inhibitors for myeloid malignancies, covering exciting combination regimens. Focusing on Dr Frey’s talk regarding CAR T-cells for B-cell ALL, the group then reflect upon the ground-breaking approval of tisagenlecleucel and the future of the anti-CD19 CAR T-cell product CTL019, including the effect of prior anti-CD19 treatment.

Share this video